There are 9 phase-3 trials in all: 6 trials that comprise the initial NDA submission in 2Q14 and 3 trials for subsequent use. All trials include the 3-DAA combination of the protease inhibitor, ABT-450 (licensed from ENTA); the NS5A inhibitor, ABT267; and the non-nucleoside polymerase inhibitor, ABT333.
Six phase-3 trials comprising initial NDA submission:
SAPPHIRE-1 (treatment-naïve GT1 w/o cirrhosis; ABT-450/ABT-267/ABT-333/ribavirin for 12w vs. placebo for 12w followed by treatment for 12w as above)—600 patients; primary outcome Sep 2013: http://www.clinicaltrials.gov/ct2/show/NCT01716585
SAPPHIRE-2 (treatment-experienced GT1 w/o cirrhosis; ABT-450/ABT-267/ABT-333/ribavirin for 12w vs. placebo for 12w followed by treatment for 12w as above)—400 patients; primary outcome Sep 2013: http://www.clinicaltrials.gov/ct2/show/NCT01715415
PEARL-2 (treatment-experienced GT1b w/o cirrhosis; ABT-450/ABT-267/ABT-333/ribavirin for 12w vs. ABT-450/ABT-267/ABT-333 (w/o ribavirin) for 12w)—210 patients; primary outcome Mar 2014: http://www.clinicaltrials.gov/ct2/show/NCT01674725
PEARL-3 (treatment-naïve GT1b w/o cirrhosis; ABT-450/ABT-267/ABT-333/ribavirin for 12w vs. ABT-450/ABT-267/ABT-333 (w/o ribavirin) for 12w)—400 patients; primary outcome Dec 2013: http://www.clinicaltrials.gov/ct2/show/NCT01767116
PEARL-4 (treatment-naïve GT1a w/o cirrhosis; ABT-450/ABT-267/ABT-333/ribavirin for 12w vs. ABT-450/ABT-267/ABT-333 (w/o ribavirin) for 12w)—300 patients; primary outcome Dec 2013: http://www.clinicaltrials.gov/ct2/show/NCT01767116
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.